• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Brazil Approval for Sanofi's Dengue Vaccine

Article

January 07, 2016.

Brazil has approved Sanofi Pasteur’s new dengue vaccine Dengvaxia as a preventive tool.

Brazil's regulator ANVISA approved the vaccine to prevent all four types of dengue in people ages 9 to 45 in regions where the tropical disease is present. More than 1.4 million Brazilians were infected with the virus this outbreak season,.

 

Related Videos